Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(25):11520-11534. doi:10.7150/thno.44829 This issue Cite

Research Paper

Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity

Zhipeng Chen1*, Zhenzhen Fan1*, Xiaowei Dou2*, Qian Zhou1*, Guandi Zeng1*, Lu Liu1, Wensheng Chen1, Ruirui Lan1, Wanting Liu1, Guoqing Ru3✉, Lei Yu4✉, Qing-Yu He1✉, Liang Chen1✉

1. Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
2. Clinical Research Center, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.
3. Department of Pathology, Zhejiang, Provincial People's Hospital, People's Hospital of Hangzhou, Medical College, Hangzhou 310014, Zhejiang Province, China.
4. Beijing Tongren Hospital, Capital Medical University, 100730 Beijing, China.
*These authors have contributed equally to this work.

✉ Corresponding author: L.C. (email: chenliangedu.cn), Q.H. (email: tqyhejnu.edu.cn), L.Y. (yulei118com) or G.R. (15868197173com).

Citation:
Chen Z, Fan Z, Dou X, Zhou Q, Zeng G, Liu L, Chen W, Lan R, Liu W, Ru G, Yu L, He QY, Chen L. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics 2020; 10(25):11520-11534. doi:10.7150/thno.44829. https://www.thno.org/v10p11520.htm
Other styles

File import instruction

Abstract

Graphic abstract

Purpose: Clinical success of precision medicine is severely limited by de novo or acquired drug resistance. It remains a clinically unmet need to treat these patients. Tumor suppressor genes (TSGs) play a critical role in tumorigenesis and impact the therapeutic effect of various treatments. Experimental Design: Using clinical data, in vitro cell line data and in vivo mouse model data, we revealed the tumor suppressive role of Clusterin in lung cancer. We also delineated the signaling cascade elicited by loss of function of CLU in NSCLC cells and tested precision medicine for CLU deficient lung cancers. Results: CLU is a potent and clinically relevant TSG in lung cancer. Mechanistically, CLU inhibits TGFBR1 to recruit TRAF6/TAB2/TAK1 complex and thus inhibits activation of TAK1- NF-κB signaling axis. Lung cancer cells with loss of function of CLU show exquisite sensitivity to TAK1 inhibitors. Importantly, we show that a significant portion of Kras mutation positive NSCLC patients are concurrently deficient of CLU and that TAK1 kinase inhibitor synergizes with existing drugs to treat this portion of lung cancers patients. Conclusions: Combinational treatment with TAK1 inhibitor and MEK1/2 inhibitor effectively shrank Kras mutation positive and CLU deficient NSCLC tumors. Moreover, we put forward a concept that loss of function of a TSG rewires signaling network and thereby creates an Achilles' heel in tumor cells which could be exploited in precision medicine.

Keywords: precision medicine, tumor suppressor gene, non-small cell lung cancer, mouse model.

Citation styles

APA
Chen, Z., Fan, Z., Dou, X., Zhou, Q., Zeng, G., Liu, L., Chen, W., Lan, R., Liu, W., Ru, G., Yu, L., He, Q.Y., Chen, L. (2020). Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics, 10(25), 11520-11534. https://doi.org/10.7150/thno.44829.

ACS
Chen, Z.; Fan, Z.; Dou, X.; Zhou, Q.; Zeng, G.; Liu, L.; Chen, W.; Lan, R.; Liu, W.; Ru, G.; Yu, L.; He, Q.Y.; Chen, L. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics 2020, 10 (25), 11520-11534. DOI: 10.7150/thno.44829.

NLM
Chen Z, Fan Z, Dou X, Zhou Q, Zeng G, Liu L, Chen W, Lan R, Liu W, Ru G, Yu L, He QY, Chen L. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics 2020; 10(25):11520-11534. doi:10.7150/thno.44829. https://www.thno.org/v10p11520.htm

CSE
Chen Z, Fan Z, Dou X, Zhou Q, Zeng G, Liu L, Chen W, Lan R, Liu W, Ru G, Yu L, He QY, Chen L. 2020. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics. 10(25):11520-11534.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use